Cargando…
Management of hepatitis B virus reactivation due to treatment of COVID-19
The world has made significant progress in developing novel treatments for COVID-19 since the pandemic began. Some treatments target the patient’s dysregulated inflammatory response during COVID-19 infection and may cause hepatitis B reactivation (HBVr) in patients with current or past hepatitis B v...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer India
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889512/ https://www.ncbi.nlm.nih.gov/pubmed/35235148 http://dx.doi.org/10.1007/s12072-022-10306-x |
_version_ | 1784661418291757056 |
---|---|
author | Yip, Terry Cheuk-Fung Gill, Madeleine Wong, Grace Lai-Hung Liu, Ken |
author_facet | Yip, Terry Cheuk-Fung Gill, Madeleine Wong, Grace Lai-Hung Liu, Ken |
author_sort | Yip, Terry Cheuk-Fung |
collection | PubMed |
description | The world has made significant progress in developing novel treatments for COVID-19 since the pandemic began. Some treatments target the patient’s dysregulated inflammatory response during COVID-19 infection and may cause hepatitis B reactivation (HBVr) in patients with current or past hepatitis B virus (HBV) infection. This review summarizes the risk and management of HBVr due to different treatments of COVID-19 in patients who have current or past HBV infection. Abnormal liver function tests are common during COVID-19 infection. Current evidence suggests that current or past HBV infection is not associated with an increased risk of liver injury and severe disease in COVID-19 patients. Among patients who received high-dose corticosteroids, various immunosuppressive monoclonal antibodies and inhibitors of Janus kinase, the risk of HBVr exists, especially among those without antiviral prophylaxis. Data, however, remain scarce regarding the specific use of immunosuppressive therapies in COVID-19 patients with HBV infection. Some results are mainly extrapolated from patients receiving the same agents in other diseases. HBVr is a potentially life-threatening event following profound immunosuppression by COVID-19 therapies. Future studies should explore the use of immunosuppressive therapies in COVID-19 patients with HBV infection and the impact of antiviral prophylaxis on the risk of HBVr. |
format | Online Article Text |
id | pubmed-8889512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer India |
record_format | MEDLINE/PubMed |
spelling | pubmed-88895122022-03-02 Management of hepatitis B virus reactivation due to treatment of COVID-19 Yip, Terry Cheuk-Fung Gill, Madeleine Wong, Grace Lai-Hung Liu, Ken Hepatol Int Review Article The world has made significant progress in developing novel treatments for COVID-19 since the pandemic began. Some treatments target the patient’s dysregulated inflammatory response during COVID-19 infection and may cause hepatitis B reactivation (HBVr) in patients with current or past hepatitis B virus (HBV) infection. This review summarizes the risk and management of HBVr due to different treatments of COVID-19 in patients who have current or past HBV infection. Abnormal liver function tests are common during COVID-19 infection. Current evidence suggests that current or past HBV infection is not associated with an increased risk of liver injury and severe disease in COVID-19 patients. Among patients who received high-dose corticosteroids, various immunosuppressive monoclonal antibodies and inhibitors of Janus kinase, the risk of HBVr exists, especially among those without antiviral prophylaxis. Data, however, remain scarce regarding the specific use of immunosuppressive therapies in COVID-19 patients with HBV infection. Some results are mainly extrapolated from patients receiving the same agents in other diseases. HBVr is a potentially life-threatening event following profound immunosuppression by COVID-19 therapies. Future studies should explore the use of immunosuppressive therapies in COVID-19 patients with HBV infection and the impact of antiviral prophylaxis on the risk of HBVr. Springer India 2022-03-02 /pmc/articles/PMC8889512/ /pubmed/35235148 http://dx.doi.org/10.1007/s12072-022-10306-x Text en © Asian Pacific Association for the Study of the Liver 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article Yip, Terry Cheuk-Fung Gill, Madeleine Wong, Grace Lai-Hung Liu, Ken Management of hepatitis B virus reactivation due to treatment of COVID-19 |
title | Management of hepatitis B virus reactivation due to treatment of COVID-19 |
title_full | Management of hepatitis B virus reactivation due to treatment of COVID-19 |
title_fullStr | Management of hepatitis B virus reactivation due to treatment of COVID-19 |
title_full_unstemmed | Management of hepatitis B virus reactivation due to treatment of COVID-19 |
title_short | Management of hepatitis B virus reactivation due to treatment of COVID-19 |
title_sort | management of hepatitis b virus reactivation due to treatment of covid-19 |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889512/ https://www.ncbi.nlm.nih.gov/pubmed/35235148 http://dx.doi.org/10.1007/s12072-022-10306-x |
work_keys_str_mv | AT yipterrycheukfung managementofhepatitisbvirusreactivationduetotreatmentofcovid19 AT gillmadeleine managementofhepatitisbvirusreactivationduetotreatmentofcovid19 AT wonggracelaihung managementofhepatitisbvirusreactivationduetotreatmentofcovid19 AT liuken managementofhepatitisbvirusreactivationduetotreatmentofcovid19 |